Share on StockTwits

Illumina (NASDAQ:ILMN) CFO Marc Stapley unloaded 1,422 shares of the company’s stock in a transaction that occurred on Monday, July 14th. The stock was sold at an average price of $177.59, for a total transaction of $252,532.98. Following the completion of the sale, the chief financial officer now directly owns 21,996 shares of the company’s stock, valued at approximately $3,906,270. The sale was disclosed in a legal filing with the SEC, which is available at this link.

Illumina (NASDAQ:ILMN) traded down 3.42% during mid-day trading on Tuesday, hitting $171.74. 1,539,689 shares of the company’s stock traded hands. Illumina has a 1-year low of $72.77 and a 1-year high of $184.49. The stock’s 50-day moving average is $170.7 and its 200-day moving average is $153.4. The company has a market cap of $22.051 billion and a P/E ratio of 125.06.

Illumina (NASDAQ:ILMN) last issued its quarterly earnings data on Tuesday, April 22nd. The company reported $0.46 EPS for the quarter, beating the Thomson Reuters consensus estimate of $0.45 by $0.01. The company had revenue of $421.00 million for the quarter, compared to the consensus estimate of $391.50 million. During the same quarter in the prior year, the company posted $0.46 earnings per share. The company’s quarterly revenue was up 27.2% on a year-over-year basis. Analysts expect that Illumina will post $2.17 EPS for the current fiscal year.

Several analysts have recently commented on the stock. Analysts at Zacks upgraded shares of Illumina from a “neutral” rating to an “outperform” rating in a research note on Tuesday, June 24th. They now have a $205.00 price target on the stock. Separately, analysts at Ned Davis Research upgraded shares of Illumina from a “sell” rating to a “neutral” rating in a research note on Monday, April 28th. Finally, analysts at Maxim Group upgraded shares of Illumina from a “hold” rating to a “buy” rating in a research note on Wednesday, April 23rd. They now have a $205.00 price target on the stock. Six research analysts have rated the stock with a hold rating, eight have assigned a buy rating and one has issued a strong buy rating to the company’s stock. The company currently has a consensus rating of “Buy” and an average target price of $150.97.

Illumina, Inc (NASDAQ:ILMN) is a developer and manufacturer of life science tools and integrated systems for the analysis of genetic variation and function.

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.